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Abstract
Trauma complicated by hemorrhagic shock (T/HS) is the leading cause of morbidity and mortality in the United States for
individuals under the age of 44 years. Initial survivors are susceptible to developing multiple organ failure (MOF), which is
thought to be caused, at least in part, by excessive or maladaptive activation of inflammatory pathways. We previously
demonstrated in rodents that T/HS results in liver injury that can be prevented by IL-6 administration at the start of
resuscitation; however, the contribution of the severity of HS to the extent of liver injury, whether or not resuscitation is
required, and the mechanism(s) for the IL-6 protective effect have not been reported. In the experiments described here, we
demonstrated that the extent of liver inflammation induced by T/HS depends on the duration of hypotension and requires
resuscitation. We established that IL-6 administration at the start of resuscitation is capable of completely reversing liver
inflammation and is associated with increased Stat3 activation. Global assessment of the livers showed that the main effect
of IL-6 was to normalize the T/HS-induced inflammation transcriptome. Pharmacological inhibition of Stat3 activity within
the liver blocked the ability of IL-6 to prevent liver inflammation and to normalize the T/HS-induced liver inflammation
transcriptome. Genetic deletion of a Stat3b, a naturally occurring, dominant-negative isoform of the Stat3, attenuated T/HS-
induced liver inflammation, confirming a role for Stat3, especially Stat3a, in preventing T/HS-mediated liver inflammation.
Thus, T/HS-induced liver inflammation depends on the duration of hypotension and requires resuscitation; IL-6
administration at the start of resuscitation reverses T/HS-induced liver inflammation, through activation of Stat3a, which
normalized the T/HS-induced liver inflammation transcriptome.
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Introduction
Trauma complicated by hemorrhagic shock (T/HS) is the
leading cause of death for those under 45 years old in the United
States [1]. Initial survivors of T/HS are particularly susceptible to
developing a systemic inflammatory response that triggers multiple
organ failure (MOF), a therapeutic challenge and the leading
cause of death among these patients [2,3]. MOF is thought to be
caused, at least in part, by excessive or maladaptive activation of
inflammatory pathways [3-5]. The liver is one of the organs most
frequently affected by T/HS, and its central role in metabolism
and homeostasis makes this organ a critical one for survival of the
host after severe injury [6,7].
We have previously demonstrated that T/HS in a rodent model
results in liver injury as evidenced by liver necrosis and
inflammation [8], apoptosis [9] and elevated transaminases [10],
and that administration of IL-6 at the start of resuscitation
prevented liver necrosis and apoptosis [8,9]. However, the
contribution of the severity of HS to the extent of liver injury,
whether or not resuscitation is required and the mechanism(s) for
the IL-6 protective effect have not been explored. In the studies
reported herein, we demonstrated that the extent of liver
inflammation induced by T/HS depends on the duration of
hypotension and requires resuscitation. We established that IL-6
administration at the start of resuscitation completely prevents
liver inflammation and is associated with increased Stat3
activation. Microarray analysis of the livers showed that the main
effect of IL-6 was to normalize the T/HS-induced inflammation
transcriptome. Pharmacological inhibition of Stat3 activity within
the liver blocked the ability of IL-6 to prevent liver inflammation
and to normalize the T/HS-induced liver inflammation tran-
scriptome. Genetic deletion of a Stat3b, a naturally occurring,
dominant-negative isoform of the Stat3, attenuated T/HS-
induced liver inflammation, confirming a role for Stat3, especially
Stat3a, in preventing T/HS-mediated liver inflammation.
Methods
Ethics Statement. Animal studies were approved by the
Baylor College of Medicine Institutional Review Board for animal
experimentation and conform to National Institutes of Health
guidelines for the care and use of laboratory animals (Protocol
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21449Approval ID: AN-1980). All animals were sacrificed under general
anesthesia as part of our shock protocol to ameliorate suffering.
Rat and mouse protocols for trauma plus hemorrhagic
shock. Adult male Sprague-Dawley rats were obtained from
Harlan (Indianapolis, IN). Stat3b homozygous-deficient (Stat3b
D/
D) mice were generated as described [11] and re-derived at Jackson
labs. Pups from heterozygous matings were tailed and genotyped
by PCR, as described, with minor modifications [11].
For the rat experiments in this study, 8-week old male Sprague-
Dawley rats (200–250 gm) were used. Rats were subjected to the
sham or T/HS protocols, as described [9,12,13] with modifica-
tions. Blood was withdrawn into a heparinized syringe episodically
to maintain the target MAP at 35 mmHg until blood pressure
compensation failed. Blood was then returned as needed to
maintain the target MAP. The amount of shed blood returned
(SBR) defined 5 different levels of shock severity reflected in the
duration of hypotension: 0% SBR (SBR0) represented the lowest
level of shock severity (duration of hypotension, 7862.5 minutes),
10% SBR (SBR10; duration of hypotension, 149641.4 minutes),
20% SBR (SBR20; duration of hypotension, 165632.7 minutes),
35% SBR (SBR35; duration of hypotension, 21167.6 minutes),
and 50% SBR (SBR50; duration of hypotension, 273624.9
minutes). At the end of the hypotensive period, rats were
resuscitated as described [9,12,13] and humanely sacrificed 60
minutes after the start of resuscitation in order to capture the first
wave of transcriptional changes. Where indicated, rats received
10 mg/kg of recombinant human IL-6 in 0.1 ml PBS at the
initiation of the resuscitation or PBS alone. Sham rats were
anesthetized and cannulated for 250 minutes but were not
subjected to hemorrhage or resuscitation. One group of rats
(UHS) was subjected to the most severe hemorrhagic shock
protocol (50% SBR), but not resuscitated and kept at the target
MAP (35 mmHg) for an additional 60 minutes (duration of
hypotension =336610.3 minutes) before sacrifice.
In the mice experiments, Stat3b
D/D mice and wild-type
littermate mice were subjected to a T/HS protocol [9,14], which
was similar to the rat protocol except that the target MAP in the
mouse was 30 mm Hg and the duration of hypotension was
300 min in all mice. Sham mice were anesthetized and
immobilized in a pair-wise fashion with T/HS mice and sacrificed
at the same time as their T/HS companion.
Rat and mouse livers were harvested immediately after sacrifice.
The right liver lobe was fixed with paraformaldehyde solution
(2%) for histological analysis and the left lobe was snap frozen in
liquid nitrogen for protein and RNA extraction.
In vivo pharmacological inhibition of Stat3. To achieve
pharmacological inhibition of Stat3 activity within the livers, rats
were randomized to receive by tail vein injection the G-rich,
quartet-forming oligodeoxynucleotide (GQ-ODN) T40214 or
non-specific (NS)-ODN (2.5 mg ODN/kg) complexed in
polyethyleneimine, as described [15], 24 hours prior to
subjecting them to the SBR50 protocol with IL-6 treatment.
The half-life of T40214 in tissues is $48 hr [16].
Myeloperoxidase (MPO) staining. To detect neutrophil
(PMN) infiltration, paraffin-embedded liver sections were
rehydrated from Xylene to PBS through a series of decreasing
concentrations of ethanol, steamed in citrate buffer and the placed on
aDAKOautostainer.Polyclonalrabbit MPOantibody-1 (Lab Vision
Corporation) was used as instructed by the manufacturer. Slides were
counterstained with hematoxylin as described before [14]. MPO
positivecellswereassessedmicroscopicallybycountingMPOpositive
cells in 20 random 61000 high power fields by an experienced
histologist blinded to the treatment each rat received. Data is
presented as number of MPO positive cells per high power field.
Immunoblotting. Levels of Stat3 activation within the livers
of rats were assessed by immunoblotting using whole-tissue
extracts of liver sections with mouse monoclonal antibodies to
Tyr705 phosphorylated (p)Stat3 (Cell Signaling Technology, Inc.,
Danvers, MA; 1:1000 dilution for each antibody). Briefly, frozen
livers were cut by cryotome into 5-micron sections and
resuspended in cell lysis buffer for pStat3 detection (Cell Death
Detection ELISA
plus Kit, Roche Diagnostics, Manheim,
Germany). The supernatant was sonicated in ice 3 times, 10
seconds each. Samples were then centrifuged and the supernatant
evaluated by Bradford assay for total protein quantification.
Protein samples (60ug total protein) were separated by SDS-PAGE
and transferred to a PVDF membrane. To detect pStat3, the
membrane was incubated overnight with specific mouse
monoclonal antibody and subsequently incubated with goat anti-
mouse antibody with horseradish peroxidase (HRP) conjugate
(Zymed, San Francisco, CA) for 1 hour. ECL agent (Amersham
Biosciences, UK) was used for detection. The membrane was then
stripped (using RestoreTM Western Blot Stripping Buffer,
PIERCE, Rockford, IL) and immuoblotting performed to detect
total Stat3 protein using mouse IgG monoclonal antibody to Stat3
(BD Biosciences, Rockville, MD; 1:1000 dilution) as described
before [9,12,13]. Detection was done using ECL agent.
Densitometry was performed using ImageQuant TL v2005
software (Amersham Biosciences, Buckinghamshire, England).
Results are expressed as the ratio of pStat3 (after background
signal subtraction) to total Stat3 signal (after background signal
subtraction) for each sample.
RNA isolation and microarray hybridization and analysis
procedures. Total RNA was isolated from 4–5 micron
cryotome sections of liver using TRIzolH Reagent (Invitrogen,
Carlsbad, California) single step RNA isolation protocol followed
by purification with RNeasyH Mini Kit (QIAGEN, Hilden,
Germany) as instructed by the manufacturer. Gene expression
profiling was performed with the Affymetrix Rat Array RAE 230A
following Affymetrix protocols used within the Baylor College of
Medicine Microarray Core Facility.
Microarray Analysis. We used Affymetrics GCOS, dChip
and Array Analyzer (Insightful Corporation) software packages for
quality assessment and statistical analysis and annotation.
Expression estimation and group comparisons were done with
Array Analyzer. Low-level analyses included background
correction, quartile normalization and expression estimation
using GCRMA [17]. One-way analysis of variance (ANOVA)
with contrasts [18] was used for group comparisons on all genes
and on the list of inflammation-related genes only. P-values were
adjusted for multiple comparisons using the Benjamini-Hockberg
method [19] with S+Array Analyzer software as described
[9,12,13]. The adjusted p-values represent false discovery rates
(FDR) and are estimates of the proportion of ‘‘significant’’ genes
that are false or spurious ‘‘discoveries’’. We used a FDR=10% as
cut-off. All microarray data are MIAME-compliant, and relevant
array data has been uploaded to Gene Expression Omnibus
(GEO) with the following series accession number: GSE27978.
Statistical Analysis. Data are presented as mean 6 standard
error of the mean (SEM) unless otherwise indicated where
appropriate. Multiple group comparisons of means were done
by one-way analysis of variance (ANOVA). Post hoc analysis was
done by Student-Newman-Keuls test for 2-group comparisons of
means. Correlation between duration of hypotension and MPO
positive cells/hpf was done for each individual study animal by
Pearson correlation coefficient. Goodness of fit was evaluated by
R-square. All statistical analyses were done on SigmaStat 2.03
(SPSS Inc., Chicago, IL).
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T/HS-induced liver inflammation depends on the
severity of shock and requires resuscitation. To
determine the contribution of the severity of shock to liver
inflammation, we assessed MPO-positive cells in the livers of rats
subjected to increasing duration of shock. The number of MPO-
positive cells/hpf increased with the duration of shock (Pearson
correlation coefficient 0.869, p,0.0001), with the number of
MPO-positive cells/hpf in the SBR50 group (12.860.09)
increased 3.1 times over sham levels (4.260.01; p,0.001;
Figure 1A).
To determine the contribution of resuscitation to liver
inflammation, we assessed MPO positive cells/hpf in the livers
of rats subjected to T/HS without resuscitation (UHS group) and
compared these results with those obtained in the sham and the
resuscitated SBR50 groups. The number of MPO-positive cells/
hpf in the UHS group (5.561.3 cells/hpf) was 2.3 times lower than
that of the SBR50 group (12.860.8 cells/hpf, p,0.01) and similar
to that of the sham group (4.260.1 cells/hpf; Figures 2A and 2B).
Thus, liver inflammation following T/HS depends on the severity
of shock and requires resuscitation.
IL-6 administration at the beginning of resuscitation
prevents T/HS-induced liver inflammation through a
mechanism that involves Stat3a activation. To evaluate
the effect of IL-6 administration on T/HS-induced liver
inflammation, we measured MPO positive cells in the livers of
rats subjected to T/HS with the most severe T/HS protocol (50%
SBR) and randomly assigned to receive either PBS (SBR50) or IL-
6 (10 mg/kg, SBR50/IL-6) at the beginning of resuscitation. The
number of MPO-positive cells/hpf in the SBR50/IL-6 group
(6.260.4) was 2.1-fold lower than that of the SBR50 group
(12.860.8 cells/hpf, p,0.01) and similar to that of the sham group
(4.260.1 cells/hpf; Figures 2A and 2B).
Stat3 is a member of the cytoplasmic protein family that is
activated by a large number of extracellular stimuli including IL-6
[20]. Stat3 is known to activate expression of genes responsible for
executing anti-inflammatory response, both in vivo and in vitro [21].
To assess if the anti-inflammatory effect of IL-6 in the liver is
mediated by Stat3 activation, we determined if Stat3 is activated in
the livers of rats resuscitated with IL-6. Extracts of cryotome
sections of the liver harvested 1 hour after IL-6 treatment were
examined by immunoblotting with mouse monoclonal antibody to
Tyr705 phosphorylated (p)Stat3 (Figure 2C). Densitometric
analysis of pStat3 bands normalized for total Stat3 indicated that
Stat3 activity in livers of IL-6-treated rats (0.7460.1 [SD]; n=4)
was increased 1.7 fold compared to the livers of placebo-treated
rats (0.4460.08 [SD]; n=4; p,0.05, ANOVA; Figure 2D).
To confirm the role of Stat3 downstream of IL-6 in mediating
its anti-inflammatory effect in the liver as well as to assess which
isoform of Stat3 mediates it, we examined whether or not these
effects of IL-6 could be reversed by pretreatment of rats with a G-
rich oligodeoxynucleotide, G-quartet (GQ)-ODN, a novel Stat3
inhibitor, that forms a rigid G-quartet structure within cells, that
inhibits the growth of tumors in which Stat3 is constitutively
activated [22,23]. Rats were treated in a blinded fashion with GQ-
ODN (SBR50/IL-6/G group) or non-specific (NS) ODN
(SBR50/IL-6/N group) 24 hours prior to being subjected to T/
HS and resuscitation with IL-6 (Figure 2C). Densitometric analysis
of pStat3 bands normalized for total Stat3 indicated that Stat3
activity in livers of SBR50/IL-6/G rats (0.2660.07 [SD]; n=3)
was decreased 1.9 fold compared to in the livers of SBR50/IL-6/
N rats (0.5060.09 [SD]; n=3; p,0.05, ANOVA; Figure 2D).
Importantly, the inhibition of Stat3 activation within the livers of
the SBR50/IL-6/G rats was accompanied by a return of the
number of MPO-positive cells (1260.4 cells/hpf) to levels similar
to those of the placebo treated (SBR50) group (12.860.8 cells/hpf,
p.0.05) and 2-fold higher than those of the IL-6 treated (SBR50/
IL-6) group (6.260.4 cells/hpf, p,0.01; Figure 2A and 2B). Stat3
activity in livers of SBR50/IL-6/N rats (0.5060.09 [SD]) was
similar to that of the SBR50/IL-6 group (0.7460.1 [SD]) and was
accompanied by a number of MPO-positive cells/hpf that was
indistinguishable from that of the SBR50/IL-6 group (Figure 2A
and 2B). Thus, pharmacological inhibition of Stat3 using GQ-
ODN in rats subjected to T/HS and resuscitated with IL-6
completely blocked IL-6-mediated Stat3 activation and IL-6-
mediated prevention of liver inflammation.
Two isoforms of Stat3 are expressed in all cells, a(p92) and
b(p83), both derived from a single gene by alternative mRNA
splicing with Stat3a predominating. While mice deficient in both
isoforms of Stat3 are embryonic lethal at day 6.5 to 7 [24] and
mice deficient in Stat3a die within 24 hr of birth, mice deficient in
Stat3b have normal survival and fertility [11]. To evaluate the
hypothesis that Stat3, in particular Stat3a, contributes to IL-6-
mediated prevention of liver inflammation and injury in the setting
of T/HS, we subjected Stat3b homozygous-deficient (Stat3b
D/D)
mice and their littermate control wild type mice to our T/HS
protocol (target MAP 30 mm Hg for 5 hr) and examined their
livers for MPO-positive cells 1 hr after the start of resuscitation.
Similar to our rat model, our mouse model of T/HS induced a 10-
fold increase in the number of MPO positive cells/hpf in the wild
type mice (16.560.79) compared to wild type mice subjected to
sham protocol (1.660.16; p,0.001; Figure 3). While the number
of MPO positive cells/hpf in the Stat3b
D/D mice subjected to T/
HS (6.560.18) was higher than that of the Stat3b
D/D mice
subjected to sham protocol (1.0860.18; p,0.001), the number of
MPO positive cells/hpf in the Stat3b
D/D mice subjected to T/HS
was 2.5-fold lower than that of WT mice subjected to T/HS
Figure 1. Effect of shock severity on liver inflammation. Rats
were subjected to sham protocol (S) or to T/HS protocol with increasing
duration of shock as indicated followed by resuscitation. The livers were
harvested 60 minutes after the start of resuscitation. Sections of
paraformaldehyde-fixed liver were stained to detect myeloperoxidase
(MPO) activity and the number of MPO-positive cells counted. Data
shown represents the number of MPO-positive cells/high power field in
20 random 1,000x fields. Curve fitting was performed and the best-
fitting curve shown; the number of MPO-positive cells increased
exponentially with duration of hypotension (Pearson correlation
coefficient=0.869, p,0.0001).
doi:10.1371/journal.pone.0021449.g001
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of Stat3 in the liver are mediated, at least in part, by Stat3a and
that Stat3b inhibits the anti-inflammatory effects of Stat3a.
Microarray analysis of the liver inflammation
transcriptome. In the context of normal wound healing and
response to injury, Stat3 has been shown to repress transcription of
pro-inflammatory genes, thereby promoting protection against
necrosis and injury in organ such as the liver and lung [18,25–27].
We have previously shown that IL-6 administration prevents T/
HS-induced liver and lung inflammation, in part by blocking NF-
kB activation and reducing pro-inflammatory cytokine production
[28,29]. To determine the mechanisms involved in this effect as
well as to evaluate the role of Stat3 downstream of IL-6, globally,
at the transcriptome level within the livers of animals subjected to
T/HS especially those genes involved in inflammation in a global
and unbiased manner, we performed Affymetrix oligonucleotide
microarray analysis with RAE 230A chips. Fifteen chips were
hybridized using mRNA isolated from 4 livers each from sham,
SBR50, and SBR50/IL-6 groups, and 3 livers from SBR50/IL-6/
G groups. All fifteen chips were included in the normalization and
expression estimation steps of the analysis and were included in the
statistical analysis and differential expression comparison. The
15,866 probesets on the RAE 230A chip represent 9,818
annotated genes or expressed sequence tags, including 694
inflammasome genes. The list of 694 genes belonging to the
inflammasome, present on the RAE 230A (Table S1) was created
by combining gene lists obtained by querying annotation
databases provided in GeneSpring and dChip, which were
derived from the Gene Ontology (GO) Consortium.
To identify genes differentially expressed among the experi-
mental groups, the data was filtered to remove genes with nearly
uniformly low expression (absent on $80% of chips). Of the 694
inflammation transcriptome genes represented on the chips, 583
genes met the requirement of this filtering process and were
included in the analysis (Table S1). One-way ANOVA (see
Materials and Methods) was then performed which identified 352
inflammation transcriptome genes with differential expression
among four experimental groups—sham, SBR50, SBR50/IL-6,
and SBR50/IL-6/G—at a False Discovery Rate (FDR) =10%
(Table S1). Of the 352 inflammation transcriptome genes whose
expression was altered among the four groups, 235 were altered in
the SBR50 vs. sham comparison (Table S2 and Figure 4A).
Among the genes whose differential expression was altered in the
SBR50 vs. sham comparison, the transcripts of the majority of
Figure 2. Effect of resuscitation, IL-6 treatment and GQ-ODN pre-treatment on T/HS-induced liver inflammation and Stat3
activation. Rats were subjected to sham protocol (Sham, n=3), unresuscitated T/HS (UHS, n=3), T/HS treated with placebo at the beginning of
resuscitation (SBR50, n=4), T/HS treated with IL-6 at the beginning of resuscitation (SBR50/IL-6, n=4), T/HS preceded by treatment with GQ-
oligodeoxynucleotide (GQ-ODN) 24 hours prior to resuscitation with IL-6 (SBR50/IL-6/G, n=3), or T/HS preceded by treatment with nonspecific-ODN
(NS-ODN) 24 hours prior to resuscitation with IL-6 (SBR50/IL-6N, n=3). The livers were harvested 60 minutes after the start of resuscitation. MPO
staining was performed in paraformaldehyde-fixed livers. Representative photomicrographs of 1000x fields of liver specimens from each
experimental group are shown (2A). Arrows indicate MPO-positive cells. In Figure 2B, MPO-positive cells were counted in 20 hpf; data presented are
the means 6 SEM of each group (n$5). Bars marked with an asterisk (*) differ significantly within the pair (p,0.05). Figure 2C shows representative
immunoblots of protein extracts of whole liver from each group, a negative control (NC) cells and positive control (PC) cells developed with
monoclonal antibodies to either phosphorylated (p)Stat3 and total (t)Stat3. Bands representing Stat3a, Stat3b, and Stat3d isoforms are indicated on
the right. Heavy lines separate representative samples from individual gels. Figure 2D shows the mean densitometric ratio of (p)Stat3 to (t)Stat3
bands 6 standard deviation of the groups (n$3 for each). Statistically significant (p,0.05) intergroup comparisons are indicated by ‘‘*’’, ‘‘{’’, and ‘‘1’’,
respectively.
doi:10.1371/journal.pone.0021449.g002
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4.0565.4 fold (range =1.07 to 45.41 fold) while transcripts of 109
genes were decreased in SBR50 vs. sham by 2.561.6 fold (range
=1.1 to 5.3 fold; Figure 4B). Importantly, 104 of the 126 genes
that were increased in the SBR50 vs. sham group, were decreased
in the SBR50/IL-6 vs. SBR50 group by 1.860.9 fold (range =1.3
to 14.3 fold) and 103 of the 109 genes that were decreased in
SBR50 group, were increased significantly in the SBR50/IL-6
group by 1.460.7 fold (range =1.2 to 2.9 fold; Figure 4B). Thus,
of the 235 genes whose transcript levels were altered in SBR50 vs.
sham group, 207 or 88% returned to sham level or were
‘‘normalized’’ in the SBR50/IL-6 group.
One-hundred and two of the 207 genes, which demonstrated
altered expression in the SBR50 vs. sham comparison and
normalization in the SBR50/IL-6 vs. SBR50 comparison, also
demonstrated altered expression in the SBR50/IL-6 vs. SBR50/
IL-6/G comparison. Ninety-seven of these 102 genes (95%) were
altered in the opposite direction as the SBR50/IL-6 vs. SBR50
comparison, consistent with the hypothesis that IL-6 normalizes
the T/HS-induced liver inflammation transcriptome alterations
largely through activation of Stat3.
The inflammation transcriptome contains a list of genes
encoding anti-inflammatory proteins that prevent inflammation
and genes encoding proteins that induce inflammation. To identify
candidate inflammation transcriptome genes whose altered
expression mediates T/HS-induced liver inflammation and injury,
we focused on both anti-inflammatory genes whose transcript
levels were decreased by T/HS and on pro-inflammatory genes
whose transcript levels were increased by T/HS. Among the genes
differentially expressed in the SBR50 vs. sham comparison, 37
anti-inflammatory genes were decreased and 100 pro-inflamma-
tory genes were increased (Figure 4C). Expression levels of 35 out
of 37 (95%) anti-inflammatory genes decreased by T/HS were
increased by IL-6 treatment; 84 of 100 (84%) of the pro-
inflammatory genes that were increased by T/HS, were decreased
by IL-6 treatment. Finally, the expression of 37% of anti-
inflammatory genes increased by IL-6 treatment was decreased
by pre-treatment with T40214; conversely 70% of pro-inflamma-
tory genes decreased by IL-6 treatment were increased by T40214
pretreatment (Figure 4C).
Pro-inflammatory genes whose expression was increased$6-fold
by T/HS were Dual specificity phosphatase 6 (Dusp6; 16.8-fold), fatty
acid binding protein 4 (Fabp4; 12-fold), alpha-2 macroglobulin (A2m,
10.1-fold), interferon regulatory factor 1 (Irf1; 9.3-fold), fatty acid binding
protein 5 (Fabp5; 9.3-fold), oxidized low density lipoprotein receptor 1
(Oldlr1; 9.0-fold), Ephrin A1 (Efna1; 7.7-fold), Phosphatidyl-inositol-3
kinase regulatory subunit polypeptide 1 (Pik3r1; 6.2-fold) and BCL2
adenovirus E1B interacting protein 3 (Bnip3; 6.1-fold, Table 1 ). The
expression of each was decreased in the IL-6-treated group by 1.8-
to 7.3-fold (Table S2). The effect of T/HS in the anti-
inflammatory subset of genes was more modest. Indeed, none of
the genes in this subset was altered more than 5.1-fold.
Discussion
The findings in our rodent protocol of T/HS demonstrated that
the extent of T/HS-induced liver inflammation following T/HS
depends on the duration of hypotension and requires resuscitation.
In previous studies, we had shown that liver inflammation induced
by T/HS is associated with liver dysfunction and 72% mortality
[12,29], and IL-6 administration at the start of resuscitation
completely reversed T/HS-induced liver inflammation and injury,
decreasing mortality 5-fold, to 15% [12,29]. In the current studies,
we established that IL-6 administration at the start of resuscitation
is capable of completely reversing liver inflammation as early as
one hour after resuscitation, and is associated with increased liver
Stat3 activation. Moreover, pharmacological inhibition of Stat3
using G-quartet oligodeoxynucleotide (GQ-ODN) T40214 devel-
oped by our group completely blocked IL-6-mediated liver Stat3
activation and prevention of inflammation. In our model of T/HS,
Stat3a was the Stat3 isoform responsible for the anti-inflammatory
effect of Stat3 in the liver. Liver microarray analysis showed that
65% of known inflammation transcriptome genes were altered in
T/HS. Administration of IL-6 ‘‘normalized’’ the expression of
88% of these genes by increasing the expression levels of 95% of
the anti-inflammatory gene transcripts whose levels were
decreased by T/HS and by decreasing transcript levels of 84%
of the pro-inflammatory genes whose levels were increased by T/
HS. Furthermore, in 55% of the cases, Stat3 mediated the
normalizing effect of IL-6 administration in the inflammation
transcriptome.
The liver is readily susceptible to injury following insults such as
hemorrhagic shock. Since the liver is responsible for maintaining
homeostasis and is a key source of energy to other organs, hepatic
injury and dysfunction associated with hemorrhagic shock can
affect other organs and lead to multiple organ failure and death
[30–32]. Liver inflammation and injury has been observed by us
and others following T/HS [10,29,33–35], which we previously
demonstrated can be prevented by administration of IL-6 at the
start of resuscitation [28,29]. However, the effect of the duration of
hypotension on the development of T/HS-induced liver inflam-
mation, as well as the mechanism(s) mediating the protective role
of IL-6 administration have not been reported.
We have previously demonstrated that T/HS induces liver
necrosis and polymorphonuclear (PMN) infiltration, which were
observed 4 hrs after resuscitation [8,29]. In the current study,
using our rodent model of T/HS we found that liver inflammation
occurs as early as 1 hour after reperfusion, and for the first time,
that its severity depends on the duration of hypotension and
requires resuscitation. Liver inflammation and injury have been
Figure 3. Effect of Stat3b ablation on T/HS-induced liver
inflammation. Stat3b homozygous-deficient (Stat3b
D/D) mice and
their littermate control wild type mice were subjected to the murine T/
HS protocol or sham protocol and their livers harvested 1 hr after the
start of resuscitation. MPO-positive cells were counted in 20 HPF of
paraformaldehyde-fixed liver. Data presented are the means 6 SEM of
each group (n$3). Significant differences are indicated (Student’s t-
test).
doi:10.1371/journal.pone.0021449.g003
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transplantation [36,37]. Upregulation of NF-kB target genes,
which induce an inflammatory cascade, has been documented to
occur early after hemorrhagic shock [28,38]. Furthermore, NF-kB
transcriptional activity has been shown to persist long after the
initial insult, leading to a sustained inflammatory process,
associated with cell injury [31]. Concordant with these data, a
possible mechanism, mediating liver inflammation and its
correlation with the severity of shock in our model of T/HS,
invokes activation of NF-kB, which has been shown to be rapidly
activated during reperfusion in hemorrhagic shock and whose
binding activity depends on the severity of shock [39]. Activation
of NF-kB can, in turn, upregulate the expression of cytokine genes
that would promote inflammation [28,29,33]. The presence of
nitric oxide, which has been implicated in the development of cell
and organ damage in settings of regional hypoxia and low flow,
both relevant to hemorrhagic shock [7], could also contribute to
our findings of increased liver inflammation. Indeed, in previous
studies, we demonstrated a nitric oxide-dependent increase of
proinflammatory cytokines after HS [14,33]. Reactive oxygen
species (ROS) generated during reperfusion may also play a role in
liver inflammation, as suggested by other investigators, given the
ability of ROS to upregulate adhesion molecules and chemotactic
factors which perpetuate the inflammatory response [7].
IL-6 is a pleiotropic cytokine, which has been shown to provide
liver protection in various settings [40-43]. IL-6-mediated
activation of Stat3 has been shown to down-regulate Stat1 activity
and to prevent inflammation by blocking interferon-c-like
response in vitro [44]. Additionally, we have previously shown that
exogenous IL-6 protected against liver PMN infiltration during
hemorrhagic shock and was associated with decreased NF-kB
activity in the liver 4 hrs after reperfusion [29]. Consistent with
Figure 4. Effect of T/HS without or with IL-6 treatment on the liver inflammation transcriptome; impact of Stat3 inhibition on the IL-
6 effect. In Figure 4A, a heat map of the liver inflammation transcriptome is shown containing those genes whose expression is altered within the 4
groups. Columns represent samples from the 4 groups examined as indicated (Sham; PBS, placebo-treated SBR50; IL, IL-6-treated SBR50/IL-6; and GQ,
animals pre-treated with G-quartet ODN prior to HS and IL-6 treatment, SBR50/IL-6/G). Rows represent genes as listed in Table S2. Red indicates a
level of expression above the mean expression of a gene within the experimental group. White indicates a level of expression at the mean within the
experimental group while blue indicates a level of expression below the mean within the experimental groups. In Figure 4B, the 235 inflammation
transcriptome genes whose expression levels were changed in SBR50 vs. sham were separated into those genes whose transcript levels were
increased in SBR50 vs. sham (126 genes; left side of panel) and those whose transcript levels were decreased in SBR50 vs. sham (109 genes; right side
of the panel). Bars shown represent mean 6 SD of the Log2-fold change in gene expression levels for each comparison. In Figure 4C, the overall effect
of T/HS in transcript levels of pro- and anti-inflammatory genes is shown. In the left side of the panel, the mean 6 SD of the Log2-fold change in gene
expression levels of 100 proinflammatory genes whose expression was increased in the SBR50 vs. sham comparison is shown (open bar). The
expression of 84 of 100 of these genes was decreased in the SBR50/IL-6 vs. SBR50 comparison (gray bar). In the right side of the panel, the mean 6 SD
of the Log2-fold change in gene expression levels of 37 anti-inflammatory genes whose expression was decreased in the SBR50 vs. sham comparison
is shown (open bar). The expression of 35 of these genes was increased in the SBR50/IL-6 vs. SBR50 comparison (gray bar).
doi:10.1371/journal.pone.0021449.g004
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prevented PMN infiltration as early as 1 hr after reperfusion.
Likely explanations for our findings are the down-modulatory
effect of IL-6 on NF-kB activity, either directly or as a result of
reduced TNF-a or IL-1 production [29] and down-regulation of
proinflammatory mediators by IL-6, which has been documented
in T/HS animals treated with exogenous IL-6 infusion [28].
The role of Stat3 activation downstream of IL-6 in the
resistance to T/HS-induced liver inflammation has not been
studied previously. In our rodent model of T/HS we found
increased Stat3 activation in the livers of rats subjected to T/HS
and treated with IL-6 at the beginning of resuscitation.
Furthermore, pharmacological inhibition of Stat3 with GQ-
ODN, 40214, decreased liver Stat3 activation and completely
prevented the anti-inflammatory effect of IL-6. Thus, IL-6-
mediated activation of Stat3 is critical for protection against liver
cell injury due to T/HS-induced inflammation.
Several studies have demonstrated that the protective role of
Stat3 against liver injury is mediated, in part, by prevention of
inflammation. Using a model of T-cell-mediated hepatitis in
IL-6
2/2 mice, Hong et al. showed that IL-6-mediated Stat3 activity
at the whole animal level protected the liver against inflammation
[45]. Other groups, using a model of partial hepatectomy, have
previously demonstrated that decreased activation of IL-6/Stat3 in
the isolated hepatocytes of ethanol-fed rats was associated with
increased liver inflammation and injury [46]. Furthermore,
IL-6-induced activation of Stat3, assessed in total liver nuclear
protein extract, has been shown to mediate liver protection against
inflammation in a model of concavalin A liver injury using
IL-6
2/2 mice [47].
Similar to bowel inflammation [48–51], Stat39s contribution to
liver inflammation is influenced in a cell-type specific fashion that
may functionally compete, depending on the cell type and the
model of liver injury. Lafdil et al. recently demonstrated, in a
model of T cell hepatitis, that deletion of Stat3 in myeloid cells
enhances inflammation while deletion of Stat3 in T cells reduces
liver inflammation [52]. Conditional deletion of Stat3 in
hepatocytes has been shown to reduce liver inflammation while
conditional deletion of Stat3 in myeloid cells enhanced liver
inflammation after CCl4 injection [53]. We have previously
demonstrated that the organ-sparing effect of IL-6 administration
in our T/HS model is mediated by Stat3 activation within
parenchymal cells, i.e. hepatocytes, cardiomyocytes, and alveolar
epithelial cells of the liver, hear, and lung, respectively. While the
anti-inflammatory effects of IL-6-activated Stat3 in our T/HS
model may be mediated by Stat3 activation within myeloid cells, it
is not likely to be mediated by Stat3 in T cells, and is most likely to
be mediated by Stat3 activated within hepatocytes. However,
future studies using the appropriate cell-specific Stat3 knockout
animals will be necessary to distinguish between these alternatives.
Stat3 has multiple functions including modulation of target
genes, which is in part due to the existence of two distinct isoforms,
a (p92) and b (p83), derived from a single gene by alternative
mRNA splicing with Stat3a predominating [54]. For example,
Stat3a is essential for induction of inflammatory genes in the liver
yet it also mediates the anti-inflammatory functions of IL-10 in
macrophages [11]. In contrast, Stat3b
D/D mice are more
susceptible to organ damage (particularly liver) and mortality
due to lipopolysaccharide injection [11,55]. Our finding of
decreased MPO-positive cells in the livers of Stat3b
D/D mice
subjected to T/HS shock in comparison to their wild type
littermates, suggest that Stat3a, and not Stat3b, is the isoform
mediating the anti-inflammatory effect of Stat3. The decrease in
inflammmation is not mediated through differential levels of
phosphorylated Stat3 within the isoform-depleted mice, but rather
through the activation of distinct transcriptomes [11].
Similar to the prior discussion of Stat39s varied role in
inflammation depending on cell type, the role of Stat3a or Stat3b
in inflammation is likely dependent on the target cell type as well
as the pro-inflammatory stimulus. This is illustrated by the fact
that Stat3a, not Stat3b, is known to mediate anti-inflammatory
functions of IL-10 in LPS-stimulated macrophages [11,56].
Additionally, Yu et al. found that in LPS-stimulated mesangial
cells, Stat3a inhibited transcriptional activation of the inducible
nitric oxide synthase (iNOS) gene by physically and functionally
interacting with NF-kB [57]. Of note, we have previously shown
that T/HS-induced inflammation and liver injury are mediated, in
part, by iNOS transcription by NF-kB [58,59].
Global and unbiased assessment of the liver inflammation
transcriptome using oligonucleotide microarray analysis deter-
mined that T/HS altered the expression of 65% of inflammation
transcriptome genes, of which 73% were pro-inflammatory and
27% were anti-inflammatory genes (S2, Figure 4B). T/HS
increased the levels of 58% of proinflammatory genes and
decreased the levels of 59% of anti-inflammatory genes. IL-6
administration prevented the T/HS-mediated changes by de-
creasing the expression of inflammation transcriptome genes
whose expression was increased by T/HS, and by increasing the
expression of inflammation transcriptome genes whose expression
was decreased by T/HS (Figure 4C), indicating that IL-6
administration had a ‘‘normalizing’’ effect on the T/HS-induced
liver inflammation transcriptome. Inhibition of Stat3 using GQ-
ODN T40214 reversed the IL-6 ‘‘normalizing’’ effect on gene
expression in 55% of the inflammation transcriptome genes
(Figure 4C). These results suggest that IL-6 administration
prevents T/HS-induced liver inflammation by opposing the effects
of T/HS on the liver inflammation transcriptome, in part, by
Stat3 activation.
Anti- and proinflammatory subsets of genes were analyzed
separately to determine the effect of T/HS in each subset of
transcripts. Gene transcript levels of the majority of proinflamma-
tory were increased by T/HS. Interestingly, IL-6 normalized the
expression of 84% of these genes, an effect that was reversed by
pre-treatment with Stat3 inhibitor in the majority of them (66%,
Table S2, Figure 4C). In our model of T/HS, proinflammatory
genes upregulated by T/HS are likely to be mediators of liver
inflammation, which is likely prevented by IL-6 normalizing effect
Table 1. Pro-inflammatory genes whose expression was
increased $6-fold by T/HS.
Pro-inflammatory Gene Name Symbol
Fold
Change
dual specificity phosphatase 6 Dusp6 16.8
fatty acid binding protein 4 Fabp4 12
alpha-2 macroglobulin A2m 10.1
interferon regulatory factor 1 Irf1 9.3
fatty acid binding protein 5 Fabp5 9.3
oxidized low density lipoprotein receptor 1 Oldlr1 9
Ephrin A Efna1 7.7
Phosphatidyl-inositol-3 kinase regulatory
subunit polypeptide 1
Pik3r1 6.2
BCL2 adenovirus E1B interacting protein 3 Bnip3 6.1
doi:10.1371/journal.pone.0021449.t001
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transcripts most upregulated following T/HS and downregulated
in the IL-6 treatment group were Dusp6, Fabp4, A2m, Irf1, Fabp5,
Oldlr1, Efna1, Pik3r1, and Bnip3. Dusp6 is a cytosolic phosphatase
with specifically inactivates extracellular signal-regulated kinase
(ERK) [60]. Oldlr1 is expressed in endothelial cells and activated
macrophages. Oldlr1 is a type II glycoprotein and acts as a
receptor for oxidized low-density lipoprotein (ox-LDL). Interaction
with ox-LDL induces ROS, reduces NO and activates NF-kB.
Old1r1 is known to induce endothelial cell injury by facilitating
inflammatory cell adhesion in an animal model of myocardial
ischemia-reperfusion [61,62]. Fabp2 and Fabp5 have been
implicated in the pathogenesis of allergic airway inflammation as
well as chronic inflammation associated with cardiovascular
disease [63,64]. A2m is a major acute phase protein with
protease-inhibitory activity, and mice deficient in A2m were
protected against lethal systemic inflammation induced by TNF
[65]. Activation of Irf1-dependent autocrine loop is known to
induce persistent inflammatory response in an animal model of
delayed inflammation [66].
Mediation of the protective effects of IL-6 in T/HS-induced
liver injury is in large part through Stat39s ability to prevent liver
inflammation. Our findings provide evidence that support the use
of IL-6 as a potential therapeutic agent to protect against liver
injury and dysfunction by blocking inflammation early after
reperfusion. Such an intervention may prevent multiple organ
failure and improve survival in the setting of trauma complicated
by severe hemorrhagic shock.
Supporting Information
Table S1 Inflammation transcriptome genes examined
in the microarray experiments. Table S1 identifies the
members of the inflammasome present on the RAE 230A chip
after filtering for uniformly low expression across chips and
describes the 352 identified as having differential expression
among four experimental groups—Sham, SBR50, SBR50/IL-6,
and SBR50/IL-6/G—at a False Discovery Rate (FDR) = 10%
via Oneway ANOVA (see Methods section). * ‘‘Y’’ indicates signal
detected above background for gene probeset in 20% or more of
the chips.
{ ‘‘Y’’ indicates significant differential gene expression
within the Sham, SBR50, SBR50/IL-6, and SBR50/IL-6/G
groups using False Discovery Rate (FDR) = 10%. ‘‘N’’ indicates
not significant differential gene expression. ‘‘NA’’ indicates genes
not included in the analysis because of not being detected in at
least 20% of the chips.
(DOC)
Table S2 Inflammation transcriptome genes differen-
tially expressed in the SBR50 vs. SHAM comparison.
Table S2 identifies the 235 members of the inflammasome whose
expression was altered among the experimental groups and
describes the pattern of dysregulation between and among
experimental groups in comparison to the SBR50 vs. Sham
animals. Genes are grouped based on direction of dysregulation,
allowing for identification of inflammasome genes dysregulated by
our trauma/hemorrhagic shock model that are ‘‘normalized’’ by
IL-6 and identification of inflammasome genes whose altered
expression is, in part, regulated through Stat3. Group 1A
represents genes increased in SBR50 vs. Sham and decreased in
SBR50/IL-6 vs. SBR50. Group 1B represents genes increased in
SBR50 vs. Sham and unchanged in SBR50/IL-6 vs. SBR50.
Group 2A presents genes decreased in SBR50 vs. Sham and
increased in SBR50/IL-6 vs. SBR50. Group 2B presents genes
decreased in SBR50 vs. Sham and unchanged in SBR50/IL-6 vs.
SBR50. Group 3 represents genes increased in SBR50 vs. Sham
and increased in SBR50/IL-6 vs. SBR50.
*Genes listed in regular
type are anti-inflammatory, while genes listed in italics are pro-
inflammatory.
{FDR: False discovery rate.
(DOC)
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